Open AccessMicrobiological Etiology of Osteomyelitis and its Empirical Therapy
Author(s) -
Natalya Pliska,
AUTHOR_ID,
Daken Tokubayeva,
AUTHOR_ID
Publication year - 2020
Publication title -
travmatologiâ ža̋ne ortopediâ
Language(s) - English
Resource type - Journals
ISSN - 1684-9280
DOI - 10.52889/1684-9280-2020-3-53-31-37
Subject(s) - medicine , vancomycin , osteomyelitis , meropenem , ceftazidime , staphylococcus aureus , amikacin , cephalosporin , levofloxacin , antibiotics , teicoplanin , imipenem , antimicrobial , surgery , microbiology and biotechnology , antibiotic resistance , biology , bacteria , pseudomonas aeruginosa , genetics
The aim of this study was to study the causative agents of osteomyelitis in the Republic of Kazakhstan and to identify the sensitivity of antibiotics for empirical therapy in the study of different groups of antimicrobial drugs. Methods. In all patients admitted with chronic osteomyelitis to the Research Institute of Traumatology and Orthopedics for the period 2017 - 2019, swabs were taken from the wound discharge, fistulous canal, punctate, as well as the selected biomaterial after surgery, in case of re-revision of the joint or its replacement in order to determine the microflora and its sensitivity to antibiotics. The results of the study showed that over the course of three years of observations in 2017 - 2019, Staphylococcus aureus is in the lead in the etiology of osteomyelitis. It was found that the sensitivity of Staphylococcus aureus is preserved to cephalosporins of the III-IV generation, fluoroquinolones, aminoglycosides, carbapenems and vancomycin. The group of tricyclic glycopeptides, which is represented by vancomycin, can be used as a backup application in cases of detection of MRSA (methicillin-resistant Staphylococcus aureus - methicillin-resistant Staphylococcus aureus). Conclusions. For 2017 - 2019, Staphylococcus aureus is the leader in the etiology of osteomyelitis. The drugs of choice in critically ill patients for this purpose may be the following antibiotics: Timentin, Ceftazidime or Ceftriaxone, Amikacin, Gentamicin, Levofloxacin, Meropenem or Imipenem, which can be used as empiric therapy